Evercore Maintains Edwards Lifesciences(EW.US) With Hold Rating, Cuts Target Price to $70

Evercore维持爱德华生命科学(EW.US)持有评级，下调目标价至70美元

moomoo资讯 · 10/01 09:31 · 评级/大行评级

Evercore analyst Vijay Kumar maintains $Edwards Lifesciences (EW.US)$ with a hold rating, and adjusts the target price from $91 to $70.

According to TipRanks data, the analyst has a success rate of 57.6% and a total average return of 5.6% over the past year.

AnalystRecentRatingAutoNews_205224_20241001_b878eb2abb1e0d8afc4d14e458b2d2d6ca307441_1727915490958050_mm_en

Furthermore, according to the comprehensive report, the opinions of $Edwards Lifesciences (EW.US)$'s main analysts recently are as follows:

There is speculation on whether the recent surge in medical technology stocks will sustain as the third-quarter financial reports approach. The sentiment is one of caution, with the third quarter often being the most challenging for the MedTech industry, inviting close examination of the strategies in place for 2025. Discussions regarding forecasts for the upcoming year might influence stock performance in the short term.
In the MedTech sector, the current utilization is sustaining its positive trend into the third quarter and the capital expenditure forecast for the coming year is considered 'healthy'. Regarding life science tools, bioprocess trends are anticipated to show improvement in the latter half of the year. However, there is ongoing discussion concerning the outlook for instruments and the impact of China's stimulus, especially in light of the recent performance of stocks within this sector.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

Evercore分析师Vijay Kumar维持$爱德华生命科学 (EW.US)$持有评级，并将目标价从91美元下调至70美元。

根据TipRanks数据显示，该分析师近一年总胜率为57.6%，总平均回报率为5.6%。

AnalystRecentRatingAutoNews_205224_20241001_b878eb2abb1e0d8afc4d14e458b2d2d6ca307441_1727915490958050_mm_sc

此外，综合报道，$爱德华生命科学 (EW.US)$近期主要分析师观点如下：

有人猜测，随着第三季度财务报告的临近，近期医疗科技股的飙升是否会持续下去。这种情绪是谨慎的，第三季度通常是医疗技术行业最具挑战性的季度，因此需要仔细研究2025年制定的战略。关于来年预测的讨论可能会在短期内影响股票表现。
在医疗科技领域，目前的利用率在第三季度一直保持积极的趋势，来年的资本支出预测被认为是 “健康的”。在生命科学工具方面，生物工艺趋势预计将在下半年显示出改善。但是，关于工具前景和中国刺激措施影响的讨论仍在继续，特别是考虑到该行业股票的近期表现。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Evercore Maintains Edwards Lifesciences(EW.US) With Hold Rating, Cuts Target Price to $70

Evercore Maintains Edwards Lifesciences(EW.US) With Hold Rating, Cuts Target Price to $70

风险及免责提示

声明